The primary purpose of Карбоплатин is applied across domains where additional symptomatic support is needed in conditions presenting with systemic or localized discomfort. It is used for managing conditions that produce significant symptomatic burden, which generally provides supportive therapeutic benefit.

This medication is commonly used across conditions presenting with acute episodes, including conditions involving epithelial ovarian carcinoma and lung cancers (both Non-Small Cell and Small Cell). It is also relevant for easing symptoms in situations involving recurrent or episodic manifestations, high-risk clinical contexts, and specific cases in the pediatric population. The therapeutic benefit generally contributes to improved comfort during periods of heightened symptoms and supports the patient during difficult episodes by easing distress.

This drug is applied in clinical settings that involve heightened systemic burden, supports patients during difficult episodes by easing distress, and assists with maintaining functional stability when symptoms are more noticeable. It is considered relevant for easing symptoms in patient groups where supportive symptom management is appropriate, such as older adults with co-existing health challenges.

Quick Fact: Relief for [Symptom]
Primary Focus	Managing symptoms related to systemic imbalance and tumor mass effects.
Key Scenarios	Used in initial systemic therapy, recurrent disease, and neoadjuvant contexts.
Patient Benefit	Supports day-to-day comfort and assists with maintaining functional stability.

Regulatory References

1. National Cancer Institute (NCI) overview

Official Eligibility and Restrictions

Карбоплатин (Carboplatin) is formally contraindicated and must not be used in the following patient populations, based on official regulatory labeling:

• Patients with a known history of severe allergic reactions (hypersensitivity) to carboplatin or any other platinum-containing compounds (such as cisplatin).
• Patients with severe bone marrow depression (myelosuppression) or significant bleeding.
• Patients who are breast-feeding, as safety for the infant is not established.

Restrictions and Special Considerations

• Renal Impairment: Use is contraindicated in patients with pre-existing severe renal impairment (creatinine clearance < 30 ml/min), unless the potential benefit outweighs the risk. Dosage must be reduced and carefully monitored in patients with lower clearance rates (e.g., < 60 ml/min).
• Pregnancy: The medicine should not be used during pregnancy as it can cause fetal harm. Women of childbearing potential and male partners must use effective contraception during and for a period after treatment.
• Age-Related Rules: Older adults (aged 65 and over) are at increased risk for toxicity (peripheral neuropathy, myelosuppression) and require careful dosage adjustment and monitoring of renal function. Pediatric use is not established.
• Vaccinations: The use of live or live-attenuated vaccines is contraindicated during carboplatin treatment due to immunosuppression.

Interaction Map: Interactions with other medicines and products — official regulatory information for Карбоплатин (Carboplatin)

---

Interaction Scope

Category	Official Regulatory Documentation
Medicinal product categories with documented interactions	Myelosuppressive agents, Nephrotoxic drugs, Ototoxic drugs, Live/live-attenuated vaccines.
Specific interacting medicines (if explicitly listed)	Yellow Fever Vaccine, Aminoglycosides, Vancomycin, Loop Diuretics, Phenytoin, Fosphenytoin.
Mechanistic basis of interactions (only if stated in label)	Additive myelosuppression, Additive organ toxicity, Physical/chemical incompatibility, Decreased plasma levels of concomitant drug.
Timing-based interaction rules (if applicable)	None explicitly documented for mandatory time separation.
Population-specific interaction notes (if applicable)	Interaction effects are more pronounced in patients with impaired renal function. Elderly patients have an increased risk of severe thrombocytopenia and neurotoxicity in combination regimens.
Interaction-related restrictions	Avoid co-administration with live vaccines. Avoid contact with aluminium-containing administration devices.

---

Interaction Classifications (High-Level)

Classification	Official Regulatory Documentation
Interaction severity classification (as defined in official documents)	Contraindicated Combination, Clinically Significant Interaction, Exposure/Potency Loss.
Regulatory basis (EMA / FDA / etc.)	Summary of Product Characteristics, FDA Prescribing Information.
Interaction-context constraints (as defined in official documents)	Combination Therapy, Immunosuppressed State, Preparation/Administration.

---

Resulting Interaction Structure

Official interaction statements:

• Co-administration with live or live-attenuated vaccines is contraindicated, as documented for the Yellow Fever Vaccine.
• Concurrent use of other myelosuppressive agents results in additive hematologic toxicity.
• Co-administration with nephrotoxic or ototoxic drugs (e.g., Aminoglycosides, Loop Diuretics) may increase or exacerbate organ-specific toxicity.
• Contact with aluminium is restricted during preparation and administration due to a physicochemical reaction that causes precipitate formation and a loss of drug potency.
• The combination with Phenytoin or Fosphenytoin may cause a decrease in the plasma levels of the anticonvulsant drugs.
• The severity of myelosuppressive interactions is more pronounced in patients with impaired renal function and elderly patients in combination regimens.

Connection to the overall interaction profile: Regulatory documents define the product's interaction structure primarily through pharmacodynamic additive toxicity involving myelosuppression and specific organ toxicities (nephrotoxicity and ototoxicity). This profile is further structured by a formal contraindication against live vaccines and a physicochemical restriction against contact with aluminium during the preparation and administration processes.

How Карбоплатин Works

Molecular Targeting: DNA Cross-linking and Inhibition

The core mechanism of Карбоплатин relies on its chemical transformation through aquation (hydrolysis) inside the cell, generating a highly reactive platinum complex. This complex preferentially forms a covalent bond with the DNA, specifically creating intrastrand cross-links at the guanine bases. This molecular damage blocks the ability of the cell to perform replication and transcription, initiating the mechanistic cascade toward cell death.

---

Cascade to Apoptosis and Cytotoxic Effect

The irreparable structural distortion of the DNA helix triggers the cell's internal damage checkpoints, resulting in Cell Cycle Arrest. When the damage cannot be repaired by the cell's endogenous mechanisms, it activates the apoptotic signaling pathway, leading to programmed cell death. This process is the physiological outcome in which apoptosis is induced in rapidly dividing cells throughout the body.

---

️ Non-Selective Effect and Mechanistic Constraints

The mechanism results in inducing apoptosis; however, the action is not selective, leading to the disruption of proliferation in healthy, fast-diving cells like the hematopoietic precursor cells in the bone marrow, a physiological effect known as myelosuppression. The drug's action can also be constrained by mechanisms of resistance, such as the cell's enhanced ability to repair DNA or chemically detoxify the platinum complex before it reaches its target.

Carboplatin is administered exclusively by intravenous (IV) infusion in a controlled, clinical setting under the supervision of a qualified physician experienced in chemotherapy. The drug is supplied as a concentrate that must be diluted with appropriate solutions, such as 5% Glucose or 0.9% Sodium Chloride, before it is administered. A critical procedural constraint is that no equipment containing aluminum parts may be used for preparation or infusion, as this contact will lead to drug degradation.

Use is structured into a cyclic regimen, typically given as a single infusion on Day 1, and repeated every four weeks (28 days). The infusion itself is administered over a duration of 15 to 60 minutes. Dosage is not fixed but is highly individualized, calculated either based on the patient's Body Surface Area (BSA) or, more commonly, using the Calvert Formula to achieve a target Area Under the Curve (AUC).

Subsequent doses cannot be given until the patient's blood counts have adequately recovered, specifically requiring a platelet count of at least 100,000/ mm^3 and a neutrophil count of 2,000/ mm^3. Furthermore, dose adjustments are mandatory for patients with impaired renal function (Creatinine Clearance < 60 mL/min); in these cases, the dose must be reduced or calculated directly using the AUC formula to account for the patient's reduced clearance rate. These instructions define the standardized approach to using the medicine.

Research evidence / Overview of studies for Карбоплатин

The research evidence for Carboplatin is derived primarily from large, formal clinical trials, including randomized controlled trials (RCTs), which compare different treatments under controlled conditions. This body of evidence describes the clinical evaluation of the drug for specific clinical situations. Research does not determine whether an individual will respond similarly, but findings describe group patterns observed in the studies.

---

Evidence for Epithelial Ovarian Carcinoma

Carboplatin was studied in research exploring its application, often in combination with other agents, for advanced epithelial ovarian, fallopian tube, or primary peritoneal cavity cancer. Large, randomized trials were conducted to evaluate Carboplatin-containing regimens and also explored comparisons against Cisplatin combinations. Research examined outcomes such as Overall Survival (OS) and Progression-Free Survival (PFS).

Findings describe the measured survival and response rate patterns observed in the studies. Comparative studies reported measurements of survival and progression endpoints for Carboplatin combinations that were broadly similar to those observed for Cisplatin combinations in the initial treatment setting. There is limited information for long-term outcomes beyond the trial follow-up periods.

---

Evidence for Non-Small Cell Lung Cancer (NSCLC)

Research examined Carboplatin, frequently in combination with a second agent, in studies of first-line therapy for adults with advanced or metastatic NSCLC. These comparative trials aimed to understand the evaluation of Carboplatin-based regimens versus other platinum-based standard treatments. Data show patterns related to measured survival outcomes that were broadly similar to those observed for Cisplatin combinations in the studied populations. Subgroup findings are uncertain regarding differences in measured survival between the two platinum agents in specific subgroups of NSCLC.

---

Evidence in Special Study Populations

Studies monitored the use of Carboplatin in various patient groups to understand how the drug's measured outcomes may be associated with these characteristics. This includes research examining older adults, evaluating outcomes reflecting daily functioning or activity level. Data for certain groups remain insufficient, for example, for patients with significant organ impairment who were often excluded from the core trials. Results apply only to the populations studied.

---

Areas of Research Uncertainty and Study Gaps

Research highlights areas where certainty remains low. Findings were mixed when measured outcomes for Carboplatin were compared against Cisplatin in some tumor types. Data are still emerging on long-term measured outcomes when Carboplatin is used alongside newer, targeted agents. Subgroup findings are uncertain where limited information exists, particularly for very specific, rare tumor characteristics.

Key Studies & References

1. Carboplatin (NCI Drug Dictionary)
2. NICE Guideline NG195: Ovarian cancer: recognising and managing

Common questions about Карбоплатин (FAQ)

---

Q: Is hair loss (alopecia) a common side effect of this drug?

Hair loss, or alopecia, is a reported side effect of this medicine according to official product information. It is often described as temporary. Hair regrowth is typically observed after the completion of treatment.

---

Q: Does this medication cause fatigue or extreme tiredness?

Official information lists unusual tiredness or weakness as a possible side effect. This feeling of fatigue is frequently connected to low red blood cell counts, a condition known as anaemia, which is a common effect of the medication that can potentially reduce energy levels.

---

Q: Do oral contraceptives (birth control pills) interact with this drug?

Regulatory information advises that this medicine may cause harm to an unborn baby. Documents state that adequate methods of contraception are required for both men and women during and for a period following treatment to avoid pregnancy.

---

Q: Can I take over-the-counter pain relievers (like ibuprofen or paracetamol/acetaminophen) with this medication?

The official product label emphasizes the requirement to inform the healthcare team—including the doctor and pharmacist—about all medications being taken. This includes any prescribed medicines, over-the-counter drugs, and all non-medicinal supplements.

---

Q: Are there any other skin or allergic side effects I should look out for?

Skin-related side effects such as rash, itching, hives, or reddening are documented in official safety profiles. Serious allergic reactions are documented to occur, with signs that may include difficulty breathing or swelling of the face or throat. These serious events are noted to increase with repeated exposure.

---

Q: Are there any restrictions on driving or operating machinery while on this medication?

Official patient information indicates that activities requiring mental alertness, such as driving or operating machinery, should be avoided if symptoms like fatigue, dizziness, or visual changes are experienced. This is due to the potential for these side effects to impair physical and cognitive function.

---

Q: What is the half-life of this drug in the body?

The half-life is a measure of how long the medicine stays in the bloodstream. Official product information states that for patients with normal kidney function, the half-life of the active form of the drug is about 2.6 to 5.9 hours (post-distribution). However, the platinum component is known to be eliminated from the body over a longer period.

---

Q: For which specific types of cancer is this drug officially approved?

According to official regulatory documents, this medicine is indicated for the treatment of advanced epithelial ovarian carcinoma, including first-line and recurrent palliative treatment. It is also approved for the treatment of small cell carcinoma of the lung.

---

Q: Does this medication interact with any herbal or dietary supplements?

Regulatory documentation emphasizes the need for healthcare providers to be fully informed about all supplements being taken before starting or continuing treatment. This includes all prescribed, over-the-counter, vitamin, and dietary or herbal supplements, as some may interact with the drug.

---

Q: What does 'AUC dosing' mean for me?

AUC stands for Area Under the Free Carboplatin Plasma Concentration Versus Time Curve. It is a measurement of the drug's total exposure in the body over time. Healthcare providers use the AUC calculation, often adjusted based on kidney function, to determine the specific, individualized dose required for treatment.

---

Q: Is diarrhea or constipation a side effect?

Yes, official safety information reports that both diarrhea and constipation are possible side effects of this medication. The management of these gastrointestinal effects typically involves monitoring and maintaining adequate fluid balance.

---

Q: Are there any pre-medication requirements before receiving this drug?

Anaphylactic reactions are reported to occur, and official documentation lists specific agents used to manage these events. Medications such as epinephrine, corticosteroids, and antihistamines are documented as agents used to manage or alleviate the symptoms of reported reactions.

---

Q: Why is this drug only administered intravenously (IV)?

According to the official product information, this medicine is manufactured as a concentrate for solution for infusion. The intravenous route is the sole administration method specified in the drug’s regulatory documentation.

Storing and Disposing of Carboplatin Injection

Unopened Carboplatin vials must be stored at controlled room temperature, specifically between 20° to 25°C (68° to 77°F), and must be protected from light. The solution should not be frozen, and the vial should be kept in its original packaging.

Stability and Handling

Stability conditions apply after the container is breached or the drug is diluted. Prepared solutions for infusion must be used or discarded within 8 hours at room temperature, or within 24 hours if refrigerated. Crucially, the preparation and administration should not use devices containing aluminum.

Disposal Requirements

Carboplatin is classified as a hazardous, cytotoxic drug. Any unused medicine, waste, or expired product must be handled and disposed of according to specialized local regulations for antineoplastic waste. All prescription medication must be kept out of the sight and reach of children.